A phase Ia/Ib study presented at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium reported good tolerability of anti-TIM-3 antibody (LY3321367) monotherapy or in combination with anti-PD-1 antibody (LY3300054) in advanced solid tumors, including HNSCC (Harding et al., 2019). The gene discussed is PDCD1; the disease is head and neck squamous cell carcinoma.